{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T14:12:29Z","timestamp":1795183949985,"version":"4.10.3"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The primary objectives of two phase II studies of fostamatinib were to evaluate efficacy (OSKIRA-Asia-1: NCT01569074) and long-term safety\/tolerability (OSKIRA-Asia-1X: NCT01640054) in patients from Asia with active RA despite MTX treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>OSKIRA-Asia-1 was a 12-week, multicentre, double-blind, placebo-controlled, parallel-group study. Patients were randomized to receive one of four fostamatinib doses (groups A\u2013D; n\u2009=\u200931, 33, 33, 33) or placebo (group E; n\u2009=\u200933). OSKIRA-Asia-1X was a long-term extension study (100\u2009mg fostamatinib qd) of patients who completed OSKIRA-Asia-1. RA signs and symptoms were measured by ACR response criteria and DAS based on a 28-joint count. Physical function status was assessed with the HAQ\u2013Disability Index. Safety findings were monitored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In OSKIRA-Asia-1, fostamatinib revealed numerical improvements in ACR 20% response (ACR20) at week 12 in group A (100\u2009mg bid) and group B (100\u2009mg bid, then 150\u2009mg qd) vs placebo. Statistically significant improvements in ACR20 and ACR50 at week 8 and in ACR70 at week 12, and statistically significant achievement in low disease activity (defined as DAS based on a 28-joint count \u22643.2 based on C-reactive protein) occurred in groups A and B. Improvement in physical function was numerically higher in group A. The most common adverse events were hypertension, diarrhoea and neutropenia. In OSKIRA-Asia-1X, the most common adverse events were nasopharyngitis, hypertension, RA and neutropenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fostamatinib achieved both statistically and clinically significant improvements in RA signs and symptoms. The safety and tolerability of fostamatinib (plus MTX) were consistent with previous studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>OSKIRA-Asia-1 trial registration: https:\/\/clinicaltrials.gov, NCT01569074; OSKIRA-Asia-1X trial registration: https:\/\/clinicaltrials.gov, NCT01640054.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa732","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T20:50:10Z","timestamp":1603745410000},"page":"2884-2895","source":"Crossref","is-referenced-by-count":31,"title":["Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Millson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D, Macclesfield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Iwata","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"2021061821311110800_keaa732-B1"},{"key":"2021061821311110800_keaa732-B2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"2021061821311110800_keaa732-B3"},{"key":"2021061821311110800_keaa732-B4","doi-asserted-by":"crossref","first-page":"vi28","DOI":"10.1093\/rheumatology\/kes278","article-title":"Evolution of treatment for rheumatoid arthritis","volume":"51","author":"Upchurch","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821311110800_keaa732-B5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/OARRR.S131668","article-title":"Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis","volume":"9","author":"Bello","year":"2017","journal-title":"Open Access Rheumatol"},{"key":"2021061821311110800_keaa732-B6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","article-title":"Treatment with biologicals in rheumatoid arthritis: an overview","volume":"4","author":"Rein","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2021061821311110800_keaa732-B7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"2021061821311110800_keaa732-B8","doi-asserted-by":"crossref","first-page":"v22","DOI":"10.1093\/rheumatology\/kes115","article-title":"Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment","volume":"51","author":"Emery","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821311110800_keaa732-B9","doi-asserted-by":"crossref","first-page":"v12","DOI":"10.1093\/rheumatology\/kes111","article-title":"Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs","volume":"51","author":"Pavelka","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821311110800_keaa732-B10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/00498251003734244","article-title":"Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey","volume":"40","author":"Sweeny","year":"2010","journal-title":"Xenobiotica"},{"key":"2021061821311110800_keaa732-B11","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/dmd.110.032151","article-title":"Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation","volume":"38","author":"Sweeny","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2021061821311110800_keaa732-B12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2165\/11591480-000000000-00000","article-title":"Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis","volume":"71","author":"Scott","year":"2011","journal-title":"Drugs"},{"key":"2021061821311110800_keaa732-B13","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/art.27438","article-title":"Genetic deficiency of Syk protects mice from autoantibody-induced arthritis","volume":"62","author":"Jakus","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021061821311110800_keaa732-B14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"2021061821311110800_keaa732-B15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2012.03.014","article-title":"Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation","volume":"129","author":"Iwata","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2021061821311110800_keaa732-B16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/art.38895","article-title":"Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy","volume":"67","author":"Iwata","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021061821311110800_keaa732-B17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0961203314560424","article-title":"Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus","volume":"24","author":"Iwata","year":"2015","journal-title":"Lupus"},{"key":"2021061821311110800_keaa732-B18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.41208","article-title":"Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase EZH2","volume":"72","author":"Zhang","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021061821311110800_keaa732-B19","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMe1006527","article-title":"Healing the Syk through kinase inhibitors","volume":"363","author":"Rivera","year":"2010","journal-title":"N Engl J Med"},{"key":"2021061821311110800_keaa732-B20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/13543784.13.7.743","article-title":"Targeting Syk as a treatment for allergic and autoimmune disorders","volume":"13","author":"Wong","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"2021061821311110800_keaa732-B21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fimmu.2016.00078","article-title":"Targeting Syk in autoimmune rheumatic diseases","volume":"7","author":"Deng","year":"2016","journal-title":"Front Immunol"},{"key":"2021061821311110800_keaa732-B22","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021061821311110800_keaa732-B23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","article-title":"An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"363","author":"Weinblatt","year":"2010","journal-title":"N Engl J Med"},{"key":"2021061821311110800_keaa732-B24","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3899\/jrheum.140238","article-title":"A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-alpha antagonist","volume":"41","author":"Genovese","year":"2014","journal-title":"J Rheumatol"},{"key":"2021061821311110800_keaa732-B25","first-page":"S198","article-title":"OSKIRA-2: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to disease-modifying antirheumatic drugs","volume":"65","author":"Dawes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021061821311110800_keaa732-B26","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/art.38851","article-title":"Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"66","author":"Weinblatt","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021061821311110800_keaa732-B27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.30114","article-title":"An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021061821311110800_keaa732-B28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jash.2014.08.013","article-title":"The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial","volume":"8","author":"Kitas","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2021061821311110800_keaa732-B29","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/annrheumdis-2014-205361","article-title":"OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy","volume":"74","author":"Taylor","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021061821311110800_keaa732-B30","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021061821311110800_keaa732-B31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jb\/mvv069","article-title":"Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside","volume":"158","author":"Tanaka","year":"2015","journal-title":"J Biochem"},{"key":"2021061821311110800_keaa732-B32","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/rheumatology\/key280","article-title":"The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?","volume":"58","author":"Tanaka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821311110800_keaa732-B33","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1182\/blood-2019-127782","article-title":"Safety profile of fostamatinib, an oral spleen tyrosine kinase inhibitor: a meta-analysis of randomized controlled trials","volume":"134","author":"Chandar","year":"2019","journal-title":"Blood"},{"key":"2021061821311110800_keaa732-B34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021061821311110800_keaa732-B35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"2021061821311110800_keaa732-B36","doi-asserted-by":"crossref","first-page":"ii26","DOI":"10.1093\/rheumatology\/kex061","article-title":"Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: summary results from the 52-week phase 3 RA-BEAM study","volume":"56","author":"Taylor","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821311110800_keaa732-B37","year":"2019"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2884\/38695178\/keaa732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2884\/38695178\/keaa732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T02:02:46Z","timestamp":1698285766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/6\/2884\/6012959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa732","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,11,30]]}}}